

Prostate cancer: “To treat, or not to treat?”

Francisco Lopez, Freddie C Hamdy and Alastair Lamb for Evidently Cochrane 20 November 2020

References

Bill-Axelsson A, Holmberg L, Mirja Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med*, 2011. 364(18): p. 1708-17. <https://www.nejm.org/doi/full/10.1056/nejmoa1011967>

Donovan JL, Hamdy FC, Lane JA, Mason M, et al. Patient Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. *N Eng J Med*, 2016. 375(15): 1425-1437. <https://www.nejm.org/doi/full/10.1056/NEJMoa1606221>

Graversen, P.H., Nielsen KT, Gasser TC, Corle DK, Madsen PO, et al. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. *Urology*, 1990. 36(6): p. 493-8. <https://pubmed.ncbi.nlm.nih.gov/2247914/>

Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Holding P, Davis M, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localised Prostate Cancer. *N Engl J Med*, 2016. 375(15): p. 1415-1424. <https://www.nejm.org/doi/full/10.1056/NEJMoa1606220>

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson S, Roobol MJ. Active surveillance for prostate cancer: A systematic review of clinico-pathologic variables and biomarkers for risk stratification. *Eur Urol*. 2015 Apr; 67(4): 619–626. doi: [10.1016/j.eururo.2014.10.010](https://doi.org/10.1016/j.eururo.2014.10.010)

Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol*. 2020 Aug; 21(8): 1023–1034. doi: [10.1016/S1470-2045\(20\)30388-0](https://doi.org/10.1016/S1470-2045(20)30388-0).

Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Fanti S, et al. Guidelines on Prostate Cancer. Arnhem (The Netherlands): European Association of Urology. [Revised 2020]. Available from: <https://uroweb.org/guideline/prostate-cancer/>

NHS. Prostate Cancer: PSA Testing. NHS.uk. Web. 11 November 2020. <https://www.nhs.uk/conditions/prostate-cancer/psa-testing/>

National Collaborating Centre for Cancer; National Institute for Health and Care Excellence (commissioner). Prostate cancer: Diagnosis and treatment. London: National Institute for Health and Care Excellence; 2019. (NICE NG131). Available from: <https://www.nice.org.uk/guidance/ng131>

Southall J. Delays in cancer diagnoses amid COVID-19 signal downstream effect on long-term outcomes. HemOnc Today. 23 July 2020. Web. 11 November 2020.

<https://www.healio.com/news/hematology-oncology/20200723/delays-in-cancer-diagnoses-amid-covid19-signal-downstream-effect-on-longterm-outcomes#>

Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday S, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020 Aug; 21(8): 1035–1044. doi:

[https://doi.org/10.1016/S1470-2045\(20\)30392-2](https://doi.org/10.1016/S1470-2045(20)30392-2)

Vernooij RWM, Lancee M, Cleves A, Dahm P, Bangma CH, Aben KKH. Radical prostatectomy versus deferred treatment for localised prostate cancer. Cochrane Database of Systematic Reviews 2020, Issue 6. Art. No.: CD006590. DOI: 10.1002/14651858.CD006590.pub3.

<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006590.pub3/full#>

Wilt, T.J., Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al., Radical prostatectomy versus observation for localised prostate cancer. N Engl J Med, 2012. 367(3): p. 203-13.

<https://pubmed.ncbi.nlm.nih.gov/22808955/>